A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Tanimilast (Primary) ; Roflumilast
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms PILLAR
- Sponsors Chiesi Farmaceutici SpA
- 12 Apr 2024 Planned End Date changed from 25 Sep 2027 to 18 Sep 2027.
- 12 Apr 2024 Planned primary completion date changed from 18 Sep 2027 to 11 Sep 2027.
- 31 Aug 2023 Planned End Date changed from 2 Aug 2025 to 25 Sep 2027.